Drug intelligence / Profile preview

IMO-2055 + FOLFIRI + cetuximab

Development stage: Unknown
Lead developer: Aceragen
Modality: Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IMO-2055 + FOLFIRI + cetuximab is a combination regimen studied in oncology clinical trials for advanced solid malignancies, notably metastatic colorectal cancer. The regimen consists of: - **IMO-2055**: an investigational Toll-like receptor 9 (TLR9) agonist designed to stimulate innate immune responses and enhance anti-tumor immunity, functioning as an immunotherapy agent. - **FOLFIRI**: a standard chemotherapy regimen containing folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. Folinic acid enhances 5-FU cytotoxicity, 5-FU is an antimetabolite that inhibits DNA synthesis, and irinotecan inhibits topoisomerase I, disrupting DNA replication and cell division[1][2]. - **Cetuximab**: a chimeric monoclonal antibody that binds to and inhibits the epidermal growth factor receptor (EGFR), blocking downstream proliferative and survival signals in cancer cells. This combination aims to integrate innate immune activation (IMO-2055), cytotoxic chemotherapy (FOLFIRI), and targeted EGFR inhibition (cetuximab) for synergistic anti-tumor effects.

Other names: IMO-2055 + FOLFIRI + cetuximab

Targets

TLR9 (Toll-like receptor 9)TS (Thymidylate synthase)EGFR (Epidermal growth factor receptor)TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on IMO-2055 + FOLFIRI + cetuximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMO-2055 + FOLFIRI + cetuximab.

Explore the full profile